• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson’s medical device sales set the Q2 pace

Johnson & Johnson’s medical device sales set the Q2 pace

July 18, 2017 By Brad Perriello

Johnson & JohnsonThe medical device business at Johnson & Johnson (NYSE:JNJ), the world’s second-largest medtech operation, today posted the highest second-quarter sales growth of its three major divisions, outpacing its pharmaceutical and consumer products segments.

The New Brunswick, N.J.-based healthcare titan said its medtech biz posted sales of $6.73 billion for the three months ended June 30, up 4.9% over the same period last year.

Overall profits were $3.83 billion, or $1.40 per share, on sales of $18.84 billion, amounting to a -4.3% bottom-line slide on sales growth of 1.9%. Adjusted to exclude 1-time items, earnings per share were $1.83, 3¢ ahead of the consensus forecast on Wall Street. Analysts on The Street were looking for sales of $18.95 billion.

“Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of Tremfya as well as the submission and approval of several key line extensions,” chairman & CEO Alex Gorsky said in prepared remarks. “The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson family of companies. Together with all of our businesses, we will continue to transform the lives of patients around the world.”

Johnson & Johnson raised its outlook for the rest of the year, saying it now expects to post full-year adjusted EPS of $7.12 to $7.22, compared with prior guidance of $7.00 to $7.15, on sales of $75.8 billion to $76.1 billion (up from $75.4 billion to $76.1 billion previously).*

JNJ shares ticked up 1.1% to $133.50 apiece today in pre-market trading.

* This article originally misreported the change in J&J’s guidance. ↩

Filed Under: MassDevice Earnings Roundup, Wall Street Beat Tagged With: Johnson and Johnson

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy